Compare Vanguard Value Index Fund ETF (VTV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Value Index Fund ETF trades at $220.59 (market cap $262.40B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Vanguard Value Index Fund ETF is far larger — about 8.7× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Value Index Fund ETF for 142 Days and Zoetis Inc for 70 Days on average.
| VTV | ZTS | |
|---|---|---|
Market Cap | $262.40B | $30.20B |
Volume | 3,293,281 | 6,175,327 |
52-Week High | $227.51 | $147.53 |
52-Week Low | $182.86 | $69.09 |
Typical Hold Time | 142 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTV trades at $219.63, up 0.65% with a bearish technical signal despite bullish moving averages. The ETF shows institutional accumulation with recent purchases by QRG Capital and Blue Edge Capital. Value strategies are gaining attention as VTV outperforms growth counterparts in 2026, offering a 2.3% dividend yield and low 0.03% expense ratio.
VTV presents a defensive value play amid market rotation from growth stocks, with strong institutional support and dividend appeal. Risks include prolonged underperformance versus broad market indices and sensitivity to interest rate changes. The current technical setup suggests cautious near-term momentum with key support at $216.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
